title: Beta2-microglobulin removal and plasma albumin levels with high cut-off hemodialysis.
abstract: OBJECTIVE
  beta2-microglobulin (beta2MG) is pivotal to the pathogenesis of dialysis-related amyloidosis. We compared the effects of high cut-off hemodialysis (HCO-HD) with those of standard high-flux hemodialysis (HF-HD) regarding the concentration and clearance of beta2MG and albumin.
  
  
  METHODS
  We enrolled ten patients with acute renal failure in a double-blind, cross-over, randomized controlled trial.
  
  
  METHODS
  Each patient received four hours of HCO-HD (estimated in vivo cutoff 50-60 kDa) and four hours of HF-HD (estimated in vivo cutoff 15-20 kDa) in random order. Statistical methods and outcome measures: As data lacked normal distribution, we used nonparametric statistical analysis. Plasma and dialysate concentrations of beta2MG and albumin were measured at baseline and after four hours of each study treatment.
  
  
  RESULTS
  We found significantly greater diffusive beta2MG clearances for HCO-HD compared to HF-HD (at the start: 71.8 ml/min vs. 5.1 ml/min; P=0.008 and at the end: 68.8 ml/min vs. 5.7 ml/min; P=0.008). We found a reduction in plasma beta2MG concentrations of -31.6% during HCO-HD compared to an increase by 25.7% during HF-HD; P=0.008. At baseline (HCO-HD: 26.0 g/L vs. HF-HD: 26.5 g/L), and at the end of both treatments, plasma albumin concentrations were comparable (HCO-HD: 25.5 g/L vs. HF-HD: 26.5 g/L; P=0.25). During HCO-HD, albumin clearance was 1.9 ml/min at the start and decreased significantly to 0.8 ml/min at the end; P=0.008. HF-HD had an albumin clearance of 0.01 ml/min.
  
  
  CONCLUSIONS
  HCO-HD was more effective in decreasing plasma beta2MG concentrations than standard HF-HD and did not reduce plasma albumin levels. Further studies of HCO-HD in the treatment of dialysis-related beta2MG accumulation appear warranted.
authors.affiliation: Intensive Care Research, Austin Hospital, University of Melbourne, Australia. michael.haase@charite.de
authors.forename: M
authors.initials: M
authors.lastname: Haase
authors.forename: R
authors.initials: R
authors.lastname: Bellomo
authors.forename: I
authors.initials: I
authors.lastname: Baldwin
authors.forename: A
authors.initials: A
authors.lastname: Haase-Fielitz
authors.forename: N
authors.initials: N
authors.lastname: Fealy
authors.forename: S
authors.initials: S
authors.lastname: Morgera
authors.forename: H
authors.initials: H
authors.lastname: Goehl
authors.forename: M
authors.initials: M
authors.lastname: Storr
authors.forename: N
authors.initials: N
authors.lastname: Boyce
authors.forename: H-H
authors.initials: HH
authors.lastname: Neumayer
mesh_terms: D058186:Acute Kidney Injury / Q000097:blood / Q000628:therapy*; D000328:Adult; D000368:Aged; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000379:methods; D012709:Serum Albumin / Q000032:analysis*; D001613:beta 2-Microglobulin / Q000097:blood*
chemical_list: D012709:Serum Albumin; D001613:beta 2-Microglobulin